Effect of sitagliptin therapy on IL-29 and its associated signaling molecules in patients with type 2 diabetes mellitus.

OBJECTIVE

The potential immunoregulatory capacity of sitagliptin on interleukin-29 (IL-29) and genes involved in its intracellular pathway were explored in type 2 diabetes mellitus (T2D).

MATERIALS AND METHODS

T2D patients treated with six months of sitagliptin (Sita), patients not treated with sitagliptin (Sita), and healthy controls (HCs) were included. IL-29 levels in the supernatant of stimulated mononuclear immune cells was determined with ELISA. The mRNA expression levels of IL-29, FOS, JUN, NF-AT2, NF-KB1, STAT1-2, IRF1, IRF3, IRF7, and IRF9 was assessed with real-time qPCR.

RESULTS

Increased protein and gene levels of IL-29 were observed in Sita group compared to HCs (p < 0.001 and p = 0.026), while those levels were diminished in Sita group in comparison with Sita group (p < 0.001 and p = 0.008). Expression of FOS, NF-AT2 and NF-KB1 in Sita patients was higher than HCs (p = 0.018, p = 0.021, and p = 0.001). A significant decrease in expression of FOS, NF-AT2, and NF-KB1 was found in Sita group versus Sita parients (p = 0.027, p = 0.003, and p = 0.002). In Sita patients, IL-29 levels were correlated to glucose metabolism parameters including FPG and HbA1c (p < 0.05 for all).

CONCLUSION

Sitagliptin administration has a regulatory effect on the aggressive expression of IL-29 and its signaling molecules including FOS, NF-AT2 and NF-KB1 in T2D.